Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

healthcare spending

- PMLiVE

Novartis wins partial reprieve for Gilenya in Germany

IQWiG now minded to give a broader recommendation for the multiple sclerosis pill

- PMLiVE

Making savings from European drugs budgets

National programmes of cuts are the order of the day

- PMLiVE

Novo pulls Tresiba from Europe’s biggest market

Firm’s new insulin will not be sold in Germany

- PMLiVE

Sobi wins European approval for oral form of orphan drug Orfadin

Expandstreatment options for rare genetic disease HT-1

- PMLiVE

The blame game

In the 'healthcare spending crisis' it’s important to look beyond sensationalist headlines

- PMLiVE

Celgene’s psoriasis pill gives ‘no added benefit’ to patients

Germany’s cost assessor IQWiG says Otezla is not value for money

- PMLiVE

Nurturing innovation in a tough environment

Much has been achieved in the UK in recent years, but the NHS still has a way to go

Shire Basingstoke

Shire links with US hospital for rare disease research

Willwork with Cincinnati Children's Hospital Medical Centre novel therapies

german flag

German pharma market to edge up to $65bn by 2020

Report finds that laws designed to curb drug prices will also slow down growth

- PMLiVE

Dendreon wins IQWiG U-turn for its immunotherapy Provenge

New data for its troubled cancer drug convinces German HTA body of its added benefit

- PMLiVE

FDA grants orphan drug status to Treeway’s ALS treatment

Amyotrophic Lateral Sclerosis drug TW001 gainsregulatory benefits

Evolution of the wearable tech revolution

Stuart Goodman delves into the world of wearables, further analysing what role they play in pharma’s future.

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links